GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

The GSK share price forecast is set at 1,733.50p, indicating a projected increase of 12.8% from the current level.See more GSK analyst ratings.Disclosure GSK Shares Soar on $2.2B Zantac Lawsuit ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

GSK has a long-term target to improve sales to more than £38bn by 2031, versus £30.3bn in 2023. Even though this is a mere trifle compared with AstraZeneca’s 2030 $80bn sales goal, the market ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...